MeiraGTx Holdings plc - Special Call Transcript
Good morning, everyone. Thank you for coming and joining us for our R&D day. I'm going to give you -- bring your attention to the forward-looking statements, which you can see on our website. And I'm going to give a very quick overview of Meira, and then we're going to focus today on our most advanced program, which is in Parkinson's disease.
I'm Zandy Forbes, and I'm the CEO of Meira. And we have a team of experts here who are going to talk about a variety of different aspects of Parkinson's disease from the economic perspective, all the way to our Phase II clinical data.
Here's the agenda. So very quickly on Meira, we formed about almost 5 years ago as a gene therapy company that was targeted to really develop gene therapy in a way that could be used potentially more broadly than for just rare diseases or as gene replacement in monogenic diseases. And in building such a company, we had both forward-looking technologies, so we have a platform of gene regulation, where we can use RNA shape to regulate different
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
